Pharmabiz: Mr. Saransh Chaudhary Featured on CDSCO Labelling Reforms

Mr. Saransh Chaudhary, President – Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre, shared his views on the recent labelling reforms announced by the Central Drugs Standard Control Organization (CDSCO) in Pharmabiz. He highlighted why these reforms are a timely and important step for India’s pharmaceutical industry.

According to Mr. Chaudhary, clear and intelligible labelling is fundamental to safe medicine use. With a focus on visual design, information hierarchy, and safety-critical details, Indian manufacturers can meet global standards.

International Standards

Globally, regulators have long recognized the role of labelling and packaging in reducing errors and preventing counterfeiting. The US FDA focuses strongly on traceability and tamper evidence through the Drug Supply Chain Security Act. The European Medicines Agency mandates unique identifiers and tamper-evident features under the Falsified Medicines Directive. Japan’s regulatory framework also stresses legible, user-friendly, and clinically safe packaging. 

These systems share a common goal: protecting patients and maintaining trust in medicines.

A Bright Future for India

India has already taken meaningful steps in the direction of upholding global standards. Building on this progress, Mr. Chaudhary reinforced that better visual design, clearer information hierarchy, and stronger emphasis on safety-critical details can make medicine packaging far easier and safer to use.

These improvements will help Indian manufacturers align more seamlessly with the expectations of global regulators and international buyers.

In sync with these changes, Venus Remedies is driven to advance the Indian pharmaceutical industry by upholding the highest standards of manufacturing, packaging, and distribution, ensuring safety at every step.